Implantica presents the third quarter (Q3 2026) on November 19 at 15:00 CET

Detailed summary

VADUZ, Liechtenstein, Nov. 12, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2026 at 15:00 CET on November 19. The interim…

VADUZ, Liechtenstein, Nov. 12, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2026 at 15:00 CET on November 19. The interim report for the third quarter (Q3 2026) will be published at 8:00 a.m. CET on the same day.

If you wish to participate via webcast, please use the following link:

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The information was sent for publication, through the agency of the contact person set out above, on November 12, 2026 at 10:00 a.m. CET.

Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop®, is an FDA approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.

In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society.

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

RefluxStop® is a treatment for GERD designed to address the root cause of acid reflux. Conventional anti-reflux surgical procedures typically rely on encircling the esophagus and are often associated with side…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.